That’s fair! I agree that a paper would be better. The counterpoint to that point is that plenty of bio startups don’t prioritize peer-reviewed papers given the time investment, and that the NIH clearly finds their data trustworthy enough to fund and conduct a phase 1 trial using their vaccine.
Abhishaike Mahajan
Karma: 448
How do you make a 250x better vaccine at 1/10 the cost? Develop it in India.
Reinforcement Learning by AI Punishment
Is there such a thing as an impossible protein?
Better antibodies by engineering targets, not engineering antibodies (Nabla Bio)
A primer on machine learning in cryo-electron microscopy (cryo-EM)
Can o1-preview find major mistakes amongst 59 NeurIPS ’24 MLSB papers?
Can AI improve the current state of molecular simulation?
Yeah I can see that; I guess what I was trying to get across was that Plasimidsaurus did do a lot of cold reachout at the start (and, when they did do it, it was high-effort, thoughtful reachouts that took into account the labs needs), but largely stopped afterwords.
Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging
Hoping to learn more about the limiting factors via people who reach out after reading this piece :)
I do somewhat buy the talent shortage + funding argument, but I also agree that there is more to the story. It may very well be the case that hundreds of these boring companies exist; I just don’t know about them. Will update this thread in a few weeks with whatever more information I learn!
That’s very true, but I do think the translation to privatization can be useful! Helps push for better UI/UX, better support, and even better infra work. This isn’t true across the board, hard to imagine a company creating something like MMSeq, but I have to imagine its true in other areas
Good CRO’s are just an example, other examples are better physical/software tooling for lab ops and better lab [object] manufacturing
Docusign does also have several other products, but that’s fair, they may very well be bloated. I do imagine that the bulk of the company is not engineering, but sales. Looking at LinkedIn confirms this: 19% engineering, 28% sales.
Sure! Agree with that all that, including in the 250x value is very much a Youtube-optimized headline than what the episode is actually about. They also obviously study clearance antibodies as well, alongside other measures of efficacy.
Past that, many people in the vaccine world are quite optimistic on Soham’s approach. There is indeed a trust problem in India, but smart people there are deeply aware of it and are trying to combat it.